Fiduciary Trust Co Has $4 Million Stock Holdings in CVS Health Co. (NYSE:CVS)

Fiduciary Trust Co decreased its stake in shares of CVS Health Co. (NYSE:CVS - Free Report) by 17.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 89,134 shares of the pharmacy operator's stock after selling 19,017 shares during the quarter. Fiduciary Trust Co's holdings in CVS Health were worth $4,001,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Whitebox Advisors LLC acquired a new stake in CVS Health in the fourth quarter valued at $249,000. Principal Financial Group Inc. lifted its stake in CVS Health by 4.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator's stock valued at $90,200,000 after purchasing an additional 66,244 shares during the last quarter. Hall Laurie J Trustee grew its holdings in CVS Health by 25,484.4% during the fourth quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator's stock worth $517,000 after purchasing an additional 11,468 shares during the period. B&D White Capital Company LLC acquired a new position in CVS Health during the fourth quarter worth approximately $417,000. Finally, Watts Gwilliam & Co. LLC lifted its position in shares of CVS Health by 9.8% in the fourth quarter. Watts Gwilliam & Co. LLC now owns 7,302 shares of the pharmacy operator's stock valued at $334,000 after buying an additional 650 shares during the last quarter. Institutional investors own 80.66% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on CVS shares. Edward Jones upgraded CVS Health from a "hold" rating to a "buy" rating in a research note on Thursday, January 30th. Wolfe Research raised their target price on shares of CVS Health from 67.00 to 70.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Leerink Partners upgraded shares of CVS Health from a "market perform" rating to an "outperform" rating and upped their price target for the company from $55.00 to $75.00 in a research note on Thursday, February 13th. Morgan Stanley restated an "overweight" rating on shares of CVS Health in a report on Tuesday, April 15th. Finally, Royal Bank of Canada increased their target price on CVS Health from $74.00 to $81.00 and gave the stock an "outperform" rating in a research note on Monday, May 5th. Three investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $74.81.

Insider Buying and Selling

In other news, SVP James David Clark sold 7,513 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the sale, the senior vice president now directly owns 8,394 shares in the company, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Michael F. Mahoney bought 30,000 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were acquired at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the transaction, the director now owns 39,356 shares in the company, valued at $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.22% of the stock is currently owned by corporate insiders.

CVS Health Trading Down 1.3 %

Shares of CVS opened at $66.98 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $72.51. The firm has a market cap of $84.45 billion, a price-to-earnings ratio of 18.30, a PEG ratio of 0.98 and a beta of 0.60. The business's fifty day moving average is $66.96 and its 200-day moving average is $59.03.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping the consensus estimate of $1.62 by $0.63. The firm had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The business's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.31 earnings per share. Equities analysts anticipate that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.97%. The ex-dividend date was Tuesday, April 22nd. CVS Health's dividend payout ratio (DPR) is 63.48%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.